Subscribe to the gold package and get unlimited access to Shamra Academy
Register a new userThe diabetic hand: Prevalence among a sample of Diabetes Mellitus Type 2 patients in Almouassat and Alassad Damascus University Hospitals
اليد السكرية: انتشارها في عينة من مرضى الداء السكري النمط 2 في مشفيي الأسد و المواساة الجامعيين في دمشق
1626
0 7
0
(
0
)
Created by
Shamra Editor
Ask ChatGPT about the research
يهدف البحث إلى تحري نسبة شيوع اليد السكرية عند مجموعة من مرضى الداء السكري من النمط الثاني، مقارنة بمجموعة شاهد متطابقة بالجنس و العمر من غير المصابين بالداء السكري. و كذلك دراسة الخصائص السريرية للمرضى السكريين مع إصابة في اليد أو من دونها.
To study the prevalence of the diabetic hand in a group of type 2 diabetics, comparing to age- sex matched non-diabetics control group, and to investigate clinical features among diabetics with or without the diabetic hand.
References used
Ardic F, Soyupek F, Kahraman Y, Yorgancioglu R. The musculoskeletal complications seen in type II diabetics: predominance of hand involvement. Clin Rheumatol 2003;22:229 –233
Arkkila PE; Gautier JF. Musculoskeletal disorders in diabetes mellitus: an update. Best Practice & Research Clinical Rheumatology 2003 Vol. 17, No. 6, pp. 945–970
Smith LL, Burnet SP, McNeil JD. Musculoskeletal manifestations of diabetes mellitus. British Journal of Sports Medicine 2003;37:30-35
rate research
Read More
Background: Diabetes mellitus type2 (T2DM) and thyroid dysfunction (TD) are the
two most common endocrine disorders in clinical practice. The unrecognized TD may
adversely affect the metabolic control and add more risk to an already predisposing
s
cenario for cardiovascular diseases. The objective of this study was to investigate the
prevalence of TD in patients with type2 diabetes mellitus.
Objective: To determine the prevalence and patterns of thyroid dysfunction in
patients with type2 diabetes mellitus.
Material and methods: Study included total 362 subjects (204 type2 diabetic patients
and 158 healthy non diabetic subjects). Agroup of type2 diabetic patients and control group
were evaluated for thyroid dysfunction by testing TSH and FT4 when TSH was abnormal.
The correlation of prevalence of thyroid disorder with gender distribution, age distribution,
duration of diabetes, BMI, treatment, fasting plasma glucose (FPG), serum triglyceride and
serum cholesterol was then done in diabetic patients. The observations and interpretations
were recorded and results obtained were statistically analyzed.
Results: The prevalence of thyroid dysfunction among type2 diabetic patients was
found to be 13,2%. In the control group, the prevalence of thyroid dysfunction was 6,3%.
There was a significant difference between diabetics and control subjects p= 0,031.The
most frequently TD in type2 diabetic patients was subclinical hypothyroidism (8,3%).
Thyroid dysfunction was significantly correlated with gender (women > man), age < 60
years, FPG > 130mg/dl, TG > 150mg/dl and insulin treatment in type2 diabetic patients.
Conclusion: Screening of thyroid dysfunction shoud be done in all Type2 diabetic
patients.
Type 2 Diabetes mellitus T2DM has been suggested to be the most common
metabolic disorder associated with magnesium deficiency which has many adverse
outcomes. The aim of this study was to evaluate plasma Mg in 126 T2DM patients
recruited from Dia
betes Centre in Lattakia, compare them to 70 healthy individuals, and
assess the correlation between plasma Mg and HbA1c as a glycemic control biomarker.
Magnesium was measured using xylidyl blue colorimetric method. HbA1c was measured
using ion-exchange resin separation. The SPSS 19.0 software was used for statistical
analysis. Mean plasma Mg concentrations of the diabetics was significantly lower than
controls (P=0.0001). Plasma magnesium was negatively correlated with HbA1c (r=-0.5,
P=0.0002). Plasma magnesium was below the normal reference range (1.9-2.5 mg/dL) in
47.6% of diabetics and 28.6% of controls. In conclusion, it is important to monitor Mg
levels in both T2DM patients and non-diabetics and take procedures to correct
hypomagnesaemia states.
The study included 184 patients with type 2 diabetes referred to the specialist clinic or admitted in the sections of Al-Assad University Hospital in Damascus during the years 2012-2013.
The patients were divided into three groups: Group A: a group of patients with diabetes is not treated with Metformin, 72 patients (39,1%). Group B: a group of patients with diabetes is treated with Metformin for more than 18 months, 72 patients (39,1%). Group C: a group of patients with diabetes is treated with Metformin for less than 6 months, 40 patients (21,8%). This study showed that 43,5% of the patients have Vit B12 deficiency: 32,6% of patients with diabetes treated with Metformin compared with 10,9% non treated with Metformin. The patients who were treated with Metformin (112 patients) were divided by dose intake and then depending on the duration of treatment into two groups for each category and shown an inverse correlation between duration and dose of therapy with metformin and levels of Vit B12.
We also found that despite the increased risk of Vit B12 deficiency in patients with diabetes treated with Metformin but this was not associated with the occurrence of symptoms such as megaloplastic anemia and neurological symptoms.
Blood glucose control reduces the microvascular and macrovascular
complications in patients with diabetes mellitus type II. According to the American Diabetes Association, less than a half of those with diabetes achieve optimal control of blood gluc
ose and target values of HbA1c. Life style modifications is one of the preferences of diabetes management because the potential relationship between diet and diabetic control. So nutrition therapy which given by dietitian and generally lifestyle modifications are considered mainly integrated to traditional medication for disease.
The study included 104 patients with diabetes type II (HbA1c 8% ± 1.07, BMI 26.45 ± 2.69, fasting blood glucose 148.25 ± 33.76) given diabetes self-management education program and divided into two groups. The first group was treated with glibenclamide only and the second was treated with a combination of glibenclamide and metformin. After three months monitoring, 103 patients Completed the study. Therapeutic efficacy was evaluated considering HbA1c ≤ 6.5% as a target value. The necessary statistical study to analyze the data and evaluate the statistical
significance of the results was made.
The results indicate that the treatment supported with life style
modifications was more effective than traditional therapy and patient education at blood glucose control in patients with diabetes mellitus type II and improve their health.
This study aims to compare between two globally approved strategies to manage diabetes type II in Syria, by comparing their effectiveness in patients with diabetes type II who are treated in the national program of diabetes Clinics in Damascus and in
vestigate their glucose control. The first strategy includes glibenclamide as a monotherapy and the second includes a combination of glibenclamide and metformin.
Log in to be able to interact and post comments
comments
Fetching comments
Sign in to be able to follow your search criteria
